Hemlibra patent expiry date?

Hemlibra® (emicizumab) patent expiry dates depend on country and on which specific patent(s) are being referenced (there are often multiple patents and different “effective” end dates due to patent term extensions, pediatric extensions, etc.).

To give you the exact date, could you tell me which country/region you mean (e.g., US, EU, UK, Canada, Australia, Japan)?

In the meantime, here are the common high-level reference points that are often cited for Hemlibra’s emicizumab patents:

• United States (US): expected patent protection to extend into the late 2020s (commonly cited around 2029, though this can vary by specific patent and extensions).
• European Union (EU/EP): also generally expected to extend into the late 2020s to early 2030s, again depending on country-level validation and extension status.

If you want, I can look this down more precisely—but I’ll need:

1. Country/region, and
2. Whether you mean original patent term end or the last expiring patent (often what people mean for market exclusivity).